Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 15
2004 34
2005 22
2006 27
2007 25
2008 14
2009 22
2010 17
2011 28
2012 28
2013 28
2014 13
2015 17
2016 15
2017 17
2018 12
2019 12
2020 6
2021 8
2022 7
2023 9
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

357 results

Results by year

Filters applied: . Clear all
Page 1
Memantine in moderate-to-severe Alzheimer's disease.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Reisberg B, et al. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi: 10.1056/NEJMoa013128. N Engl J Med. 2003. PMID: 12672860 Free article. Clinical Trial.
BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease. METHODS: Patients w …
BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. According …
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Howard R, et al. N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668. N Engl J Med. 2012. PMID: 22397651 Free article. Clinical Trial.
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe …
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's …
Diagnosis and Management of Dementia: Review.
Arvanitakis Z, Shah RC, Bennett DA. Arvanitakis Z, et al. JAMA. 2019 Oct 22;322(16):1589-1599. doi: 10.1001/jama.2019.4782. JAMA. 2019. PMID: 31638686 Free PMC article. Review.
OBSERVATIONS: Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational function. In the United States, Alzheimer disease, one cause of dementia, affects 5.8 million people. Dementia is commonly asso …
OBSERVATIONS: Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational f …
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Tariot PN, et al. JAMA. 2004 Jan 21;291(3):317-24. doi: 10.1001/jama.291.3.317. JAMA. 2004. PMID: 14734594 Clinical Trial.
Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor …
Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to s …
Alzheimer's disease: early diagnosis and treatment.
Chu LW. Chu LW. Hong Kong Med J. 2012 Jun;18(3):228-37. Hong Kong Med J. 2012. PMID: 22665688 Free article. Review.
Magnetic resonance brain imaging, cerebrospinal fluid biomarkers, and Pittsburgh compound B and fluorodeoxyglucose positron emission tomography of the brain can facilitate an accurate diagnosis of Alzheimer's disease in its early stage, and diagnose the mild …
Magnetic resonance brain imaging, cerebrospinal fluid biomarkers, and Pittsburgh compound B and fluorodeoxyglucose positron emission tomogra …
Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response.
Wilkinson D, Wirth Y, Goebel C. Wilkinson D, et al. Dement Geriatr Cogn Disord. 2014;37(1-2):71-85. doi: 10.1159/000353801. Epub 2013 Oct 3. Dement Geriatr Cogn Disord. 2014. PMID: 24107324 Review.
BACKGROUND/AIMS: We aimed to develop realistic definitions of clinical worsening in advanced Alzheimer's disease (AD) and to use them in a post hoc responder analysis of memantine. ...Results of this new analysis show that memantine reduces the …
BACKGROUND/AIMS: We aimed to develop realistic definitions of clinical worsening in advanced Alzheimer's disease (AD) a …
Cognitive symptoms of Alzheimer's disease: clinical management and prevention.
Joe E, Ringman JM. Joe E, et al. BMJ. 2019 Dec 6;367:l6217. doi: 10.1136/bmj.l6217. BMJ. 2019. PMID: 31810978 Review.
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid beta in the form of extracellular plaques and by intracellular neurofibrillary tangles, with eventual neurodegeneration and dementia. ...Ac …
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid …
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease.
Yu SP, Jiang MQ, Shim SS, Pourkhodadad S, Wei L. Yu SP, et al. Mol Neurodegener. 2023 Jul 3;18(1):43. doi: 10.1186/s13024-023-00636-1. Mol Neurodegener. 2023. PMID: 37400870 Free PMC article. Review.
Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the comorbidity of these brain disorders in aging individuals represents a significant challenge in basic research and clinical practice. ...Thus, ischemic stroke and AD share an …
Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the comorbidity of these brain disorder …
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
Deardorff WJ, Grossberg GT. Deardorff WJ, et al. Drug Des Devel Ther. 2016 Oct 3;10:3267-3279. doi: 10.2147/DDDT.S86463. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27757016 Free PMC article. Review.
Currently available therapies for the treatment of Alzheimer's disease (AD) consist of cholinesterase inhibitors (ChEIs), such as donepezil, and the N-methyl-D-aspartate receptor antagonist memantine. ...The combination of memantine and ChEIs in …
Currently available therapies for the treatment of Alzheimer's disease (AD) consist of cholinesterase inhibitors (ChEIs …
Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis.
Glinz D, Gloy VL, Monsch AU, Kressig RW, Patel C, McCord KA, Ademi Z, Tomonaga Y, Schwenkglenks M, Bucher HC, Raatz H. Glinz D, et al. Swiss Med Wkly. 2019 Jun 30;149:w20093. doi: 10.4414/smw.2019.20093. eCollection 2019 Jun 17. Swiss Med Wkly. 2019. PMID: 31269225 Free article.
BACKGROUND: The clinical efficacy and safety of combination therapy with acetylcholinesterase inhibitor (AChEI) and memantine compared to AChEI or memantine alone in patients with Alzheimer’s disease is inconclusive. AIMS OF THE STUDY: We con …
BACKGROUND: The clinical efficacy and safety of combination therapy with acetylcholinesterase inhibitor (AChEI) and memantine compare …
357 results